549835
2,4,6-Tris(dimethylamino)-1,3,5-triazine
96%
Synonym(s):
Altretamine, Hexamethylmelamine
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Empirical Formula (Hill Notation):
C9H18N6
CAS Number:
Molecular Weight:
210.28
EC Number:
MDL number:
UNSPSC Code:
12352100
PubChem Substance ID:
NACRES:
NA.22
Recommended Products
Assay
96%
mp
171-175 °C (lit.)
functional group
amine
SMILES string
CN(C)c1nc(nc(n1)N(C)C)N(C)C
InChI
1S/C9H18N6/c1-13(2)7-10-8(14(3)4)12-9(11-7)15(5)6/h1-6H3
InChI key
UUVWYPNAQBNQJQ-UHFFFAOYSA-N
Looking for similar products? Visit Product Comparison Guide
General description
2,4,6-Tris(dimethylamino)-1,3,5-triazine exhibits antitumor activity.
Signal Word
Warning
Hazard Statements
Precautionary Statements
Hazard Classifications
Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
Target Organs
Respiratory system
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Personal Protective Equipment
dust mask type N95 (US), Eyeshields, Gloves
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Triazines and related products. Part 26. Synthesis and chemistry of bicyclic analogues of the antitumour drug 2, 4, 6-tris (dimethylamino)-1, 3, 5-triazine (hexamethylmelamine).
Langdon SP, et al.
Journal of the Chemical Society. Perkin Transactions 1, 993-998 (1984)
Nina Keldsen et al.
Gynecologic oncology, 88(2), 118-122 (2003-02-15)
To evaluate the activity of oral Altretamine in women with epithelial ovarian carcinoma who responded (PR or CR) to first line chemotherapy but relapsed within 6 months. The protocol was later amended to include patients with relapse within 12 months.
Peter Dornan et al.
Chemical communications (Cambridge, England), (31)(31), 3645-3647 (2008-07-31)
A novel method for the cyclotrimerization of dimethylcyanamide to form hexamethylmelamine has been developed using an aluminium amide catalyst; detailed DFT modelling of the catalytic cycle supports a triple insertion, nucleophilic ring closure, deinsertion mechanism.
Yong Soon Kwon et al.
Journal of Korean medical science, 24(4), 679-683 (2009-08-06)
The aim of this study was to assess the efficacy of consolidation therapy with hexamethylmelamine (HMM) in patients with advanced epithelial ovarian cancer (EOC). Patients treated at our hospital between January 1997 and November 2006 and in documented clinical complete
D S Alberts et al.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 14(2), 224-228 (2004-04-17)
This report provides follow-up progression-free survival (PFS) and median survival data for women who achieved clinical complete remission (cCR) from stage III ovarian cancer after first-line therapy and were treated with altretamine consolidation therapy. Patients who enrolled in the SWOG
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service